New York, New York--(Newsfile Corp. - October 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7091/65214_07983442142dc8e4_001full.jpg
To: All Persons or Entities who purchased MyoKardia, Inc. ("MyoKardia" or the "Company") (NASDAQ: MYOK) stock prior to October 5, 2020.
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of MyoKardia to Bristol Myers Squibb (NYSE: BMY). Under the terms of the deal, Bristol Myers Squibb will acquire MyoKardia for $225.00 per share in cash.To learn more about the action and your rights, go to:
https://www.zlk.com/mna2/myokardia-inc-information-request-form
or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.
The MyoKardia merger investigation concerns whether the Board of MyoKardia has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/65214
